Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Capital Expenditures: 2019-2024

Historic Capital Expenditures for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $180,000.

  • C4 Therapeutics' Capital Expenditures rose 2423.08% to $302,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $482,000, marking a year-over-year decrease of 48.78%. This contributed to the annual value of $180,000 for FY2024, which is 89.46% down from last year.
  • Per C4 Therapeutics' latest filing, its Capital Expenditures stood at $180,000 for FY2024, which was down 89.46% from $1.7 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Capital Expenditures registered a high of $5.5 million during FY2022, and its lowest value of $180,000 during FY2024.
  • Moreover, its 3-year median value for Capital Expenditures was $1.7 million (2023), whereas its average is $2.5 million.
  • In the last 5 years, C4 Therapeutics' Capital Expenditures soared by 330.38% in 2022 and then crashed by 89.46% in 2024.
  • Over the past 5 years, C4 Therapeutics' Capital Expenditures (Yearly) stood at $650,000 in 2020, then spiked by 96.46% to $1.3 million in 2021, then soared by 330.38% to $5.5 million in 2022, then plummeted by 68.92% to $1.7 million in 2023, then slumped by 89.46% to $180,000 in 2024.